explore -WSS

explore

author：hotspot 2025-09-30 13:13:57 - browse：172

Diversity in clinical trials concept — Adobe

The persistent lack of diversity among participants in clinical trials is a critical issue that is harming both populations that have long been left out of pivotal medical studies and the entire biomedical research enterprise, according to the authors of a report released Tuesday by the National Academies of Sciences, Engineering and Medicine.

Describing the need to move away from trials that focus largely on white men as “urgent,” the report’s authors called for a paradigm shift that gives less power to institutions that fund and conduct clinical research and more to communities under study. The sternly worded report said funding to include and recruit more diverse participants should be a priority that is enforced and said such investments could eventually lead to massive cost savings as the nation’s health disparities are reduced.

“An equitable clinical research enterprise would include trials and studies that match the demographics of the disease burden under study,” the report said. “However, we remain far from achieving this goal.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： How doctors’ personal politics affect patients

WSS

Sepsis can kill a child within hours. Here's how hospitals are fighting back

Chemotherapy before breast cancer surgery might fuel metastasis

Dems pitch expanding Medicare power to negotiate drug prices

New lawsuit accuses health insurer Cigna of denying claims in bulk

What causes rare myocarditis in young men after Covid vaccines?

Truvian presents data for its desktop blood

hotspot

explore

focus

Trump demands the U.S. pay no more for drugs than other countries … again

Most antidepressants don't work on kids, teens, study finds

The high cost of giving birth even with insurance

AI for drug discovery: Experts on separating hype from reality

Heart attack and stroke risk calculators need revising

Device maker Teleflex to acquire urology company for $600M

Cancer drug shortages should be causing more outrage

Most antidepressants don't work on kids, teens, study finds

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Roche’s Alnylam deal shows drug firms interested in heart drugs

hotspot

Brain MRIs reveal impact of 'toxic stress' on Black children

Truvian presents data for its desktop blood

Most antidepressants don't work on kids, teens, study finds

Search called off for baby washed away in Pennsylvania flash flood

STAT Report: Patient voices and perspectives

PBM executives asked to testify by House panel

knowledge

focus

explore

knowledge